BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28089878)

  • 1. Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab.
    Marsh RA; Fukuda T; Emoto C; Neumeier L; Khandelwal P; Chandra S; Teusink-Cross A; Vinks AA; Mehta PA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):635-641. PubMed ID: 28089878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
    Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.
    Marsh RA; Lane A; Mehta PA; Neumeier L; Jodele S; Davies SM; Filipovich AH
    Blood; 2016 Jan; 127(4):503-12. PubMed ID: 26644451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.
    Bhoopalan SV; Cross SJ; Panetta JC; Triplett BM
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):711-717. PubMed ID: 33037919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
    Kothari A; Ngwube A; Hayashi R; Murray L; Davis J; Haut P; Loechelt BJ; Shenoy S
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1321-5. PubMed ID: 25840334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease.
    Bhatt ST; Schulz G; Hente M; Slater A; Murray L; Shenoy S; Bednarski JJ
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28030. PubMed ID: 31599480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity.
    Fitch T; Lane A; McDonnell J; Bleesing J; Jordan M; Kumar A; Khandelwal P; Khoury R; Marsh R; Chandra S
    Transplant Cell Ther; 2024 Jan; 30(1):101.e1-101.e12. PubMed ID: 37821080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation.
    Dong M; Emoto C; Fukuda T; Arnold DE; Mehta PA; Marsh RA; Vinks AA
    Br J Clin Pharmacol; 2022 Jan; 88(1):248-259. PubMed ID: 34182590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine/Melphalan 100 mg/m
    Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease.
    Khandelwal P; Bleesing JJ; Davies SM; Marsh RA
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2011-2018. PubMed ID: 27543157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
    Marsh RA; Kim MO; Liu C; Bellman D; Hart L; Grimley M; Kumar A; Jodele S; Myers KC; Chandra S; Leemhuis T; Mehta PA; Bleesing JJ; Davies SM; Jordan MB; Filipovich AH
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1625-31. PubMed ID: 24035782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
    Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome.
    Admiraal R; Jol-van der Zijde CM; Furtado Silva JM; Knibbe CAJ; Lankester AC; Boelens JJ; Hale G; Etuk A; Wilson M; Adams S; Veys P; van Kesteren C; Bredius RGM
    Clin Pharmacokinet; 2019 Dec; 58(12):1609-1620. PubMed ID: 31131436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study.
    Sahdev I; Brochstein J; Werther N; Stiles J
    J Pediatr Hematol Oncol; 2020 Nov; 42(8):e718-e722. PubMed ID: 32890079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders.
    Madden LM; Hayashi RJ; Chan KW; Pulsipher MA; Douglas D; Hale GA; Chaudhury S; Haut P; Kasow KA; Gilman AL; Murray LM; Shenoy S
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1467-1472. PubMed ID: 27164064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
    Patel K; Parmar S; Shah S; Shore T; Gergis U; Mayer S; van Besien K
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):456-61. PubMed ID: 26524732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
    Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S;
    Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
    Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders.
    Chandra S; Mizuno K; Zhao J; Davies SM; Marsh RA; Fukuda T; Setchell KDR; Vinks AA; Mehta PA
    Br J Clin Pharmacol; 2022 Jan; 88(1):115-127. PubMed ID: 34075614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.